N Engl J Med
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Jhaveri KL, Neven P, Casalnuovo ML, et al
In this Phase 3, open-label study, patients with ER-positive, HER2-negative advanced breast cancer and ESR1 mutations treated with imlunestrant had significantly longer progression-free survival compared with those who received standard therapy. Treatment with imlunestrant-abemaciclib significantly improved progression-free survival compared with imlunestrant alone, regardless of ESR1-mutation status.
Previous Article
- • Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- • Imlunestrant Monotherapy: Phase 1a/1b EMBER Study
- • Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
- • Pharmacodynamics from EMBER-2
- • Imlunestrant: First Approval
- • Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer
- • ESR1 Mutations in Breast Cancer
